Literature DB >> 24688782

New techniques for assessing response after hypofractionated radiotherapy for lung cancer.

Sarah A Mattonen1, Kitty Huang1, Aaron D Ward1, Suresh Senan1, David A Palma1.   

Abstract

Hypofractionated radiotherapy (HFRT) is an effective and increasingly-used treatment for early stage non-small cell lung cancer (NSCLC). Stereotactic ablative radiotherapy (SABR) is a form of HFRT and delivers biologically effective doses (BEDs) in excess of 100 Gy10 in 3-8 fractions. Excellent long-term outcomes have been reported; however, response assessment following SABR is complicated as radiation induced lung injury can appear similar to a recurring tumor on CT. Current approaches to scoring treatment responses include Response Evaluation Criteria in Solid Tumors (RECIST) and positron emission tomography (PET), both of which appear to have a limited role in detecting recurrences following SABR. Novel approaches to assess response are required, but new techniques should be easily standardized across centers, cost effective, with sensitivity and specificity that improves on current CT and PET approaches. This review examines potential novel approaches, focusing on the emerging field of quantitative image feature analysis, to distinguish recurrence from fibrosis after SABR.

Entities:  

Keywords:  Lung cancer; hypofractionated radiotherapy (HFRT); image feature analysis; positron emission tomography (PET); stereotactic radiotherapy

Year:  2014        PMID: 24688782      PMCID: PMC3968559          DOI: 10.3978/j.issn.2072-1439.2013.11.09

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  70 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy.

Authors:  Marco Ravanelli; Davide Farina; Mauro Morassi; Elisa Roca; Giuseppe Cavalleri; Gianfranco Tassi; Roberto Maroldi
Journal:  Eur Radiol       Date:  2013-07-09       Impact factor: 5.315

3.  Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly.

Authors:  Shervin M Shirvani; Jing Jiang; Joe Y Chang; James W Welsh; Daniel R Gomez; Stephen Swisher; Thomas A Buchholz; Benjamin D Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-09-11       Impact factor: 7.038

4.  Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.

Authors:  Kristi Hendrickson; Mark Phillips; Wade Smith; Lanell Peterson; Kenneth Krohn; Joseph Rajendran
Journal:  Radiother Oncol       Date:  2011-08-27       Impact factor: 6.280

Review 5.  Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer.

Authors:  David Palma; Suresh Senan
Journal:  Curr Opin Oncol       Date:  2011-03       Impact factor: 3.645

6.  Illustrative cases of false positive biopsies after stereotactic body radiation therapy for lung cancer based on abnormal FDG-PET-CT imaging.

Authors:  Mamta Singhvi; Percy Lee
Journal:  BMJ Case Rep       Date:  2013-01-22

7.  Quantitative assessment of change in regional disease patterns on serial HRCT of fibrotic interstitial pneumonia with texture-based automated quantification system.

Authors:  Ra Gyoung Yoon; Joon Beom Seo; Namkug Kim; Hyun Joo Lee; Sang Min Lee; Young Kyung Lee; Jae Woo Song; Jin Woo Song; Dong Soon Kim
Journal:  Eur Radiol       Date:  2012-08-24       Impact factor: 5.315

8.  When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

Authors:  Geoffrey R Oxnard; Michael J Morris; F Stephen Hodi; Laurence H Baker; Mark G Kris; Alan P Venook; Lawrence H Schwartz
Journal:  J Natl Cancer Inst       Date:  2012-08-27       Impact factor: 13.506

9.  A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.

Authors:  Mark A Henderson; David J Hoopes; James W Fletcher; Pei-Fen Lin; Mark Tann; Constantin T Yiannoutsos; Mark D Williams; Achilles J Fakiris; Ronald C McGarry; Robert D Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-25       Impact factor: 7.038

10.  Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.

Authors:  Charles C Vu; Robert Matthews; Bong Kim; Dinko Franceschi; Thomas V Bilfinger; William H Moore
Journal:  Nucl Med Commun       Date:  2013-10       Impact factor: 1.690

View more
  8 in total

1.  Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control.

Authors:  Marguerite Tyran; Nathalie Charrier; Julien Darreon; Anne Madroszyk; Agnes Tallet; Naji Salem
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 2.  Pulmonary quantitative CT imaging in focal and diffuse disease: current research and clinical applications.

Authors:  Mario Silva; Gianluca Milanese; Valeria Seletti; Alarico Ariani; Nicola Sverzellati
Journal:  Br J Radiol       Date:  2018-01-12       Impact factor: 3.039

3.  SBRT for lung oligometastases: Who is the perfect candidate?

Authors:  Pierina Navarria; Fiorenza De Rose; Anna Maria Ascolese
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-30

4.  Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study.

Authors:  Melissa A Frick; Gary D Kao; Louise Aguarin; Chimbu Chinniah; Samuel Swisher-McClure; Abigail T Berman; William P Levin; Keith A Cengel; Cristina DeCesaris; Stephen M Hahn; Jay F Dorsey; Charles B Simone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-07-02       Impact factor: 7.038

5.  Impact of Reconstruction Algorithms on CT Radiomic Features of Pulmonary Tumors: Analysis of Intra- and Inter-Reader Variability and Inter-Reconstruction Algorithm Variability.

Authors:  Hyungjin Kim; Chang Min Park; Myunghee Lee; Sang Joon Park; Yong Sub Song; Jong Hyuk Lee; Eui Jin Hwang; Jin Mo Goo
Journal:  PLoS One       Date:  2016-10-14       Impact factor: 3.240

Review 6.  Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer.

Authors:  Liting Shi; Yaoyao He; Zilong Yuan; Stanley Benedict; Richard Valicenti; Jianfeng Qiu; Yi Rong
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

7.  Tumor Volume Regression during and after Radiochemotherapy: A Macroscopic Description.

Authors:  Paolo Castorina; Gianluca Ferini; Emanuele Martorana; Stefano Forte
Journal:  J Pers Med       Date:  2022-03-26

8.  Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology.

Authors:  Weimiao Wu; Chintan Parmar; Patrick Grossmann; John Quackenbush; Philippe Lambin; Johan Bussink; Raymond Mak; Hugo J W L Aerts
Journal:  Front Oncol       Date:  2016-03-30       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.